Revolutionizing the treatment of dermatitis
Carocell Bio is transforming the way that inflammatory diseases are treated
We are at the forefront of a peptide-based, anti-inflammatory approach to heal and promote healthier skin and help treat skin-related conditions such as atopic dermatitis, as well as a host of other inflammation based diseases.
'Inflammaging'
A significant component of skin ageing is related to inflammation and this affects everone as they grow older.
Our treatment, which is developed for topical application to the skin, has the potential to be used as a highly effective anti-ageing treatment.
Treatment of Atopic Dermatitis (eczema )
Atopic dermatitis (eczema) is the most common skin disease, and is often a chronic condition
Current treatments carry significant safety risks
Our lead peptide, JEL0305, works in biopsies from patients with Atopic Dermatitis
Our novel peptide technology will safely revolutionise the management of dermatitis
Prevention - stops eczema coming back
Our patented peptide can not only treat eczema – if its use is continued, it will be able to prevent the disease coming back
Giving you healthier, happier skin over the longer-term
Carocell Bio would be more than happy to discuss any of these indications
Our Research and Data.
We have proprietary peptide-based anti-inflammation technology, with highly potent and highly selective therapeutic peptides that inhibit intracellular mitogen-activated protein kinase (MAPK, p38).
Our portfolio of novel molecules inhibit the inflammatory cascade, combining them with a nanoparticle delivery technology that can be applied to the skin.
Our Leadership Team
Carocell Bio’s leadership team has extensive global experience in drug development – from idea through to market
Dr Mike Davies MD, FRCS
CEO & Founder
- Edinburgh University
- Fully-trained surgeon
- More than 25 years’ experience in drug development
- Invested >$650,000 into Carocell Bio
Anuj Madhok, PHD
CFO/CBO
- Biopharma executive experienced across strategy / BD / finance.
- Value creation >$2B (incl. $700m exit)
Scientific and Clinical Advisors
Professor Anne Dickinson, PhD
Emerita Professor, Newcastle University and Director of Newcastle Cellular Therapies Facility
